Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. [electronic resource]
Producer: 20180705Description: e0194329 p. digitalISSN:- 1932-6203
- Amides
- Antiviral Agents -- economics
- Benzofurans -- economics
- Carbamates
- Cost-Benefit Analysis -- methods
- Cyclopropanes
- Drug Therapy, Combination -- economics
- Female
- France
- Genotype
- Hepacivirus -- genetics
- Hepatitis C, Chronic -- complications
- Humans
- Imidazoles -- economics
- Kidney Failure, Chronic -- complications
- Liver Cirrhosis -- complications
- Male
- Middle Aged
- Models, Economic
- Quality-Adjusted Life Years
- Quinoxalines -- economics
- RNA, Viral -- genetics
- Randomized Controlled Trials as Topic
- Renal Dialysis
- Sulfonamides
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.